Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-30

Stabilizing the exposure of neutralization epitopes on HIV-1 envelope glycoprotein trimer vaccines

Objective

The impact of HIV/AIDS on world healthcare is tremendous, particularly in the Third World. To curtail the HIV epidemic a cheap and effective vaccine is urgently needed, but despite massive research efforts no vaccine is available yet. Although most vaccines work by inducing neutralizing antibodies, HIV has evolved many ways to limit the induction and binding of neutralizing antibodies. The challenge is to engineer Env subunit vaccines that do induce neutralizing antibodies efficiently. One aspect that has been highly underappreciated is conformational heterogeneity of Env. Conformational flexibility is exerted at three different levels. First, flexible variable loops and N-glycans protruding from the conserved protein core cause “local flexibility” at the protein surface. Second, movement between the conserved inner and outer domain of gp120 causes “tertiary flexibility”. Third, movement of the three gp120 protomers in the trimeric complex, resembling a flower that opens and closes, causes “quaternary flexibility”. These three levels of flexibility provide very unstable targets for recognition by low affinity B cell receptors on naïve B cells, diminishing the chance of efficient B cell activation and the secretion of neutralizing antibodies. Using a number of novel structure-based vaccine design strategies that include the introduction of stabilizing disulfide bonds, we intend to remove the undesirable flexibility on Env trimers to provide a homogeneous and stable target to B cells. This should result in stabilized Env immunogens that are better in inducing neutralizing antibodies compared to the current state-of-the art Env vaccines. This is a highly interdisciplinary project on the crossroads of immunology and protein chemistry and should result in protein immunogens that elicit improved neutralizing antibody responses against HIV and should provide answers to fundamental questions on how B cells “see” protein immunogens.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

ERC-2011-StG_20101109
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

ERC-SG - ERC Starting Grant

Host institution

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
EU contribution
€ 1 499 943,00
Address
MEIBERGDREEF 15
1105AZ Amsterdam
Netherlands

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Beneficiaries (1)

My booklet 0 0